Background: Cystic fibrosis (CF) negatively impacts upon health-related quality of life (HRQoL) and survival. Adherence to nebulised treatments is low; improving adherence is hypothesised to reduce rates of exacerbation requiring intravenous antibiotics and lung function decline. Results: If effective, the adherence intervention is expected to produce an additional 0.19 QALYs and cost savings of £64,078 per patient. Across all analyses, the intervention dominated current care. Over a 5-year period, the intervention is expected to generate cost savings of £49.5million for the estimated 2,979 CF patients with Pseudomonas aeruginosa currently aged 16 or above in the UK. If applied to a broader population of adult CF patients receiving any nebulised therapy, the expected savings could be considerably greater.
Methods
Conclusions:If effective, the adherence intervention is expected to produce additional health gains at a lower cost than current CF care. The economic analysis should however be revisited upon completion of the full RCT. More generally, the analysis suggests that considerable gains could be accrued through the implementation of adherence interventions which shift care from expensive hospital-based rescue to community-based prevention.